Inspired by natural molecular scaffolds, Ommio Health strives to utilize our proprietary platform to improve and expand the impacts that these compounds have on human health and veterinary applications.
Ommio Health
A biotechnology company focused on developing novel therapeutics and delivery platforms that seek to improve human and animal health and well-being.
Ommio is derived from the Greek “omoiostasia” or homeostasis. Many illnesses and health challenges are the direct result of our biological systems deviating from this delicate balance. Ommio Health is focused on developing novel therapeutics, pharmaceutical ingredients, and delivery platforms capable of modulating biological systems and improving human and animal health and well-being.
MISSION
APPROACH
Our proprietary chemistry allows us to create a platform by which natural therapeutic scaffolds are utilized as a starting point. With a focus on improving the biological activity of these compounds, our unique solution focuses on increased stability, targeted and controlled release, and enhanced bioavailability.
We are focused on the development of active pharmaceutical ingredients (APIs) that provide solutions to underserved and underperforming aspects of human health and well-being. Our initial indications include non-addictive pain cessation, sleep disorders, weight and metabolism management, and anxiety relief. Additionally, our unique approach provides access to bioactive polymeric structures, capable of forming novel therapeutic biomaterials. These platforms are being applied in parallel toward a veterinary program focused on pain and anxiety relief.
Meet the Team
Management
Konstantine Drakonakis, PE
Co-Founder / CEO
Konstantine is an experienced entrepreneur and investor with 20 years of building high tech therapeutic and advanced material companies.
He is presently the a managing venture partner for Connecticut Innovations, Climate Tech Fund. Konstantine is also a partner with the Pritzker Vlock Family Office, where he was a founding member and director of LaunchCapital’s New Haven CT Office, the firm’s early-stage-focused venture firm. He developed a portfolio of 40 companies, representing over 100 transactions and more than $1 billion in syndication. Konstantine has also been a founder and operator of four tech companies: 6K, Katharos, PlazMod and Ommio Health. He is a board member/director at 6K (where he was the Founding Executive Chairman and former CSO), EpiEP, TearSolutions, and Iridia. Konstantine is also an active member in the university entrepreneurial ecosystem.
READ MORE▼
Nick Breault
Vice President of Operations
Nick has demonstrated exceptional leadership in startups, building and leading cross-functional teams to successfully bring cutting-edge medical devices to market.
His extensive knowledge of polymers has been instrumental in driving innovation in advanced manufacturing and medical device development. A passionate entrepreneur and skilled strategist with a firm grasp of regulatory requirements, Nick has orchestrated successful FDA interactions and successfully expedited the approval process and launch of new devices. Combining strong operational skills with business acumen, he established manufacturing facilities for polymer processing and medical device production. Nick's leadership extends to implementation, budgeting, financial reporting, and due diligence activities, ensuring smooth operation and financial health of ventures.
READ MORE▼
Carl Christianson, Ph.D.
Chief Operating Officer
Carl is a seasoned entrepreneur, having been a founder, co-founder, and advisor on numerous projects in the AgTech and BioTech sectors over the past decade.
His background as a natural product chemist has driven his interest in these areas. He performed his Ph.D. in Chemistry at Boston College and postdoctoral research at the Max Planck Institute of Colloids and Interfaces, in Berlin Germany. While working in innovative sectors, Carl has spent time at the state and Federal levels, educating and collaborating with lawmakers to effectively understand and craft regulations for new scientific markets. He is dedicated to the craft of building companies and teams to efficiently and effectively tackle complex issues associated with the advancement of human health and safety.
READ MORE▼
